Armata Pharmaceuticals: First patient dosed in Phase 2a portion of AP-SA02 study

Armata Pharmaceuticals announced that the first patient has been dosed in the Phase 2a portion of the company’s diSArm study of AP-SA02 as a potential treatment for Staphylococcus aureus bacteremia. Initiation of the Phase 2a portion of the study follows Data Review Committee review of positive safety and tolerability data from the Phase 1b portion. Armata has received a $16.3M award to advance development of AP-SA02 from the Department of Defense through the Medical Technology Enterprise Consortium managed by the Naval Medical Research Command with funding from the Defense Health Agency and Joint Warfighter Medical Research Program.